Rollins, Inc. Share Price Target ‘$46.74’, now 1.3% Upside Potential

DirectorsTalk Interviews

Rollins, Inc. which can be found using ticker (ROL) now have 9 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $52.00 and $37.00 calculating the mean target share price we have $46.74. (at the time of writing). Given that the stocks previous close was at $46.13 this now indicates there is a potential upside of 1.3%. The day 50 moving average is $45.42 and the 200 day MA is $41.58. The market capitalization for the company is 22.67B. The stock price for the company is currently is currently $46.79 USD

The potential market cap would be $22,971,187,903 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 51.99, revenue per share of $6.49 and a 15.94% return on assets.

Rollins, Inc. (Rollins) is an international services company. The Company provides pest and wildlife control services and protection against termite damage, rodents, and insects to both residential and commercial customers through its wholly owned subsidiaries and independent franchises located in approximately 70 countries, including United States, Canada, Australia, Europe, and Asia with international franchises in Canada, Central and South America, the Caribbean, Europe, the Middle East, Asia, Africa, and Australia. Rollins operates under three business lines, namely Residential, which includes pest control services protecting residential properties from common pests, including rodents, insects and wildlife; Commercial, which consist of workplace pest control solutions for customers across diverse end markets such as healthcare, foodservice, logistics, and Termite, which consist of traditional and baiting termite protection services and ancillary services for customers.

Share on:

Latest Company News

Genflow Biosciences links ageing science with MASH research

MASH gives Genflow Biosciences a defined opportunity to explore how its SIRT6-based gene therapy research could address metabolic liver damage, inflammation and fibrosis.

GCP Infrastructure reports 8.0% portfolio yield and stronger balance sheet

GCP Infrastructure Investments has reported a 98.60 pence net asset value, portfolio valuation of £810.4 million and further debt and asset sale updates.

Plus500 expands US trading offering with new Single Stock Futures

Plus500 has launched Single Stock Futures in the US, broadening customer access to CME Group-listed contracts and leading US stocks.

Clarkson reports record first-half profit and raises interim dividend

Clarkson Plc reported record first-half profit, lifted interim dividend and said full-year performance is expected to be materially ahead of market expectations.

Ilika plc reaches a commercial turning point as new markets emerge for Stereax and Goliath (video)

Dr Tom McColm of Morphose Capital Partners explains why the company may be approaching an important commercial inflection point.

Alien Metals notes start of 8,300m West Pilbara drill program

Alien Metals notes GreenTech has started an 8,300 metre drill programme at Whundo and Munni Munni in Western Australia.

    Search